drugset / Trial / NCT06745323
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).
Timeline
- Start
- 2025-02-26
- Primary completion
- 2029-08-10
- Completion
- 2029-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tarlatamab | Protein / enzyme biologic | — | Intravenous |